Literature DB >> 33589595

Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents.

He-Ming Zhou1, Ji-Gang Zhang1, Xue Zhang1, Qin Li2.   

Abstract

Cancer stem cells (CSCs) show a self-renewal capacity and differentiation potential that contribute to tumor progression and therapy resistance. However, the underlying processes are still unclear. Elucidation of the key hallmarks and resistance mechanisms of CSCs may help improve patient outcomes and reduce relapse by altering therapeutic regimens. Here, we reviewed the identification of CSCs, the intrinsic and extrinsic mechanisms of therapy resistance in CSCs, the signaling pathways of CSCs that mediate treatment failure, and potential CSC-targeting agents in various tumors from the clinical perspective. Targeting the mechanisms and pathways described here might contribute to further drug discovery and therapy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33589595      PMCID: PMC7884707          DOI: 10.1038/s41392-020-00430-1

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  287 in total

1.  Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.

Authors:  Premkumar Vummidi Giridhar; Karin Williams; Andrew P VonHandorf; Paul L Deford; Susan Kasper
Journal:  Cancer Res       Date:  2019-01-09       Impact factor: 12.701

2.  A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.

Authors:  Andrew H Ko; Noelle LoConte; Margaret A Tempero; Evan J Walker; R Kate Kelley; Stephanie Lewis; Wei-Chou Chang; Emily Kantoff; Michael W Vannier; Daniel V Catenacci; Alan P Venook; Hedy L Kindler
Journal:  Pancreas       Date:  2016-03       Impact factor: 3.327

3.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

4.  Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.

Authors:  Robert L Coleman; Katelyn F Handley; Robert Burger; Graziela Zibetti Dal Molin; Robert Stagg; Anil K Sood; Kathleen N Moore
Journal:  Gynecol Oncol       Date:  2020-02-07       Impact factor: 5.482

5.  Transplantable hematopoietic stem cells in human fetal liver have a CD34(+) side population (SP)phenotype.

Authors:  N Uchida; T Fujisaki; A C Eaves; C J Eaves
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.

Authors:  Paul P Szotek; Rafael Pieretti-Vanmarcke; Peter T Masiakos; Daniela M Dinulescu; Denise Connolly; Rosemary Foster; David Dombkowski; Frederic Preffer; David T Maclaughlin; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

7.  Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling.

Authors:  Kristian Almstrup; Christina E Hoei-Hansen; Ute Wirkner; Jonathon Blake; Christian Schwager; Wilhelm Ansorge; John E Nielsen; Niels E Skakkebaek; Ewa Rajpert-De Meyts; Henrik Leffers
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

8.  HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance.

Authors:  Shou Liu; Ji Shin Lee; Chunfa Jie; Min Ho Park; Yoichiro Iwakura; Yogin Patel; Mithil Soni; David Reisman; Hexin Chen
Journal:  Cancer Res       Date:  2018-01-30       Impact factor: 12.701

9.  An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance.

Authors:  Ningning Li; Roya Babaei-Jadidi; Federica Lorenzi; Bradley Spencer-Dene; Philip Clarke; Enric Domingo; Eugene Tulchinsky; Robert G J Vries; David Kerr; Yihang Pan; Yulong He; David O Bates; Ian Tomlinson; Hans Clevers; Abdolrahman S Nateri
Journal:  Oncogenesis       Date:  2019-02-19       Impact factor: 7.485

10.  A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.

Authors:  Stephen Couban; Giulia Benevolo; William Donnellan; Jennifer Cultrera; Steffen Koschmieder; Srdan Verstovsek; Gregory Hooper; Christian Hertig; Maneesh Tandon; Natalie Dimier; Vikram Malhi; Francesco Passamonti
Journal:  J Hematol Oncol       Date:  2018-09-24       Impact factor: 17.388

View more
  47 in total

1.  Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells.

Authors:  Austin T K Hoke; Michelle R Padget; Kellsye P Fabian; Anjali Nandal; Gary L Gallia; Marijo Bilusic; Patrick Soon-Shiong; James W Hodge; Nyall R London
Journal:  Cancer Res Commun       Date:  2021-12

2.  Overexpression of transmembrane protein 102 implicates poor prognosis and chemoresistance in epithelial ovarian carcinoma patients.

Authors:  Yi-Jou Tai; Cheng-Miao Ou; Ying-Cheng Chiang; Chi-Fang Chang; Chi-An Chen; Wen-Fang Cheng
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

3.  Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.

Authors:  Hye-Young Min; Ho Jin Lee; Young-Ah Suh; Honglan Pei; Hyukjin Kwon; Hyun-Ji Jang; Hye Jeong Yun; Hyeong-Gon Moon; Ho-Young Lee
Journal:  Br J Cancer       Date:  2022-05-21       Impact factor: 9.075

Review 4.  Macrophage-Derived Extracellular Vesicles: A Promising Tool for Personalized Cancer Therapy.

Authors:  Antonella Barone; Nicola d'Avanzo; Maria Chiara Cristiano; Donatella Paolino; Massimo Fresta
Journal:  Biomedicines       Date:  2022-05-27

Review 5.  Cancer Stem Cells and Their Possible Implications in Cervical Cancer: A Short Review.

Authors:  Riccardo Di Fiore; Sherif Suleiman; Rosa Drago-Ferrante; Yashwanth Subbannayya; Francesca Pentimalli; Antonio Giordano; Jean Calleja-Agius
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

Review 6.  Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research.

Authors:  Yan Hu; Yajie Sun; Chao Wan; Xiaomeng Dai; Shuhui Wu; Pui-Chi Lo; Jing Huang; Jonathan F Lovell; Honglin Jin; Kunyu Yang
Journal:  J Nanobiotechnology       Date:  2022-04-13       Impact factor: 10.435

Review 7.  Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy.

Authors:  Hend M Nawara; Said M Afify; Ghmkin Hassan; Maram H Zahra; Akimasa Seno; Masaharu Seno
Journal:  Biomedicines       Date:  2021-05-02

Review 8.  Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance.

Authors:  Saeedeh Keyvani-Ghamsari; Khatereh Khorsandi; Azhar Rasul; Muhammad Khatir Zaman
Journal:  Clin Epigenetics       Date:  2021-05-29       Impact factor: 6.551

Review 9.  Gastric Cancer Stem Cells: A Glimpse on Metabolic Reprogramming.

Authors:  Martina Addeo; Giuseppina Di Paola; Henu Kumar Verma; Simona Laurino; Sabino Russi; Pietro Zoppoli; Geppino Falco; Pellegrino Mazzone
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

10.  Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.

Authors:  Viktorija Juric; Heiko Düssmann; Martine L M Lamfers; Jochen H M Prehn; Markus Rehm; Brona M Murphy
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.